US/UK/Canada

Share

Quotes

ColdZyme is the future of cold relief. By breaking the viral cycle at the first signs of symptoms, the product helps cut illness duration in half and speeds up recovery.
Sana Alajmovic
We offer a unique, evidence-based alternative in a market dominated by outdated products. ColdZyme reduces viral load by 94 percent, helping you avoid putting your life on hold.
Sana Alajmovic
My focus is to lead Enzymatica into its next phase of growth. ColdZyme is a consumer favorite with clinically proven efficacy – we have the potential to become a global leader.
Sana Alajmovic
Pick a time period -
Tags ( Active)

Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion

Third quarter January-September · Net sales · Net sales reached SEK 35.6 (28.4)reached SEK 15,0 million.(12,6) · The operating result totaled SEK -41.1 (million. -38.3) million. · The operating · Earnings per share, basic and diluted,result totaled SEK were SEK -0.17 (-0.23).-8,2 (-6,4) · Cash flow from operating activities formillion. the period totaled SEK -41.4 (-40.0) · Earnings per million.share, basic anddiluted, were SEK  -0.03 (-0.04). · Cash flow fromoperatingactivities

Quarterly report Q2/2025: Strong development in Sweden and increased international activity

Second quarter January-June · Net sales · Net sales reached SEK 20.6 (15.8)reached SEK 8.3 million.(6.4) · The operating result totaled SEK -32.9 (million. -31.9) million. · The operating · Earnings per share, basic and diluted,result totaled SEK were SEK -0.13 (-0.19).-14.9 (-13.5) · Cash flow from operating activities formillion. the period totaled SEK -29.9 (-26.3) · Earnings per million.share, basic and  diluted, were SEK-0.06 (-0.08). · Cash flow fromoperatingactivities totaled

Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion

First quarter   · Net sales amounted to SEK 12.3million (9.4). · Operating result amounted to SEK-18.0 million (-18.4) · Earnings per share, before and afterdilution, amounted to SEK -0.07 (-0.11). · Cash flow from operating activitiesamounted to SEK -8.5 million (-7.3).  Comments from CEO Claus Egstrand "Enzymatica’s progress and future prospects are clearly reflected in the strong first quarter of 2025. ColdZyme continues to perform strongly in the pharmacy sector, growing faster than the overall market and resulting in additional

Year-end report 2024: Strong performance in core markets – preparing for international growth

Fourth quarter January-December · Net sales ·     Net sales reached SEK 45.6 millionreached SEK 17.2 (50.9).million (15.8). · The operating result totaled SEK -52.1 · The operating million (-48.1).result totaled SEK · Earnings per share, basic and diluted,-13.7 million ( were-13.8). SEK -0.28 (-0.30). · Earnings per · Cash flow from operating activities forshare, basic and the period totaled SEK -60.5 million (diluted, were SEK -40.3).-0.05 (-0.09). · Net cash totaled SEK 73.0 million ( · Cash flow

Interim report Q3/2024: Focus on developing existing and new markets

Third quarter January-September · Net sales · Net sales reached SEK 28.4 (35.1)reached SEK 12.6 million.(13.3) · The operating result totaled SEK -38.3 (million. -34.3) million. · The operating · Earnings per share, basic and diluted,result totaled SEK were SEK -0.23 (-0.22).-6.4 (-8.7) · Cash flow from operating activities formillion. the period totaled SEK -40.0 (-37.7) · Earnings per million.share, basic anddiluted, were SEK-0.04 (-0.06). · Cash flow fromoperatingactivities totaled

Bulletin from annual general meeting of Enzymatica AB (publ) on May 7, 2024

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Enzymatica AB (publ) held its annual general meeting on May 7, 2024. At the annual general meeting, the following resolutions were made. Income statements and balance sheets The general meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet. Disposition of the company’s profit or loss The general meeting resolved, in

Interim report Q1/2024: MDR certification opens up great commercial opportunities

First quarter · Net sales reached SEK 9.4 (13.0) million. · The operating result totaled SEK -18.4 (-14.4) million. · Earnings per share, basic and diluted, were SEK -0.11 (-0.09). · Cash flow from operating activities totaled SEK -7.3 (-12.2) million.   CEO Comment “Sales for the first quarter were lower than the same period last year, which in its entirety is due to the low partner sales. In the Swedish market, sales were up by 21% compared to the same quarter last year, and our market share continues to increase. During the quarter, ColdZyme was MDR certified as

Notice of Annual General Meeting 2024 in Enzymatica AB (publ)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The annual general meeting of Enzymatica AB (publ), reg. no. 556719-9244, will be held on 7 May 2024 at 14:30 CET, Elite Hotel Ideon, Scheelevägen 27 in Lund.Notification etc. Those who wish to participate in the annual general meeting must: (i)       be listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances as per the record date of 26 April 2024;

Enzymatica announces outcome of new rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors for Enzymatica (”Enzymatica” or ”Company”) today announces the outcome of the new rights issue with preferential rights for existing shareholders that was published on 16 February 2024 (the “Rights issue”

Enzymatica publishes information memorandum about rights issue of shares

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, RUSSIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors of Enzymatica AB (publ) ("Enzymatica" or the "Company") has published an information memorandum regarding the rights issue of shares that Enzymatica announced on February 16, 2024 (the "

Enzymatica’s rights issue is secured to 100 percent

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors of Enzymatica AB (publ) (”Enzymatica” or ”the Company”) decided on February 16, 2024, to carry out a rights issue of SEK 27.4 million with preferential rights for existing shareholders. The Board of

Year-end report 2023: Scientific and regulatory progress generating international interest

Fourth quarter January-December · Net sales reached SEK · Net sales reached SEK 50.9 (48.9)15.8 (16.6) million. million. · The operating result · The operating result totaled SEK -48.1 (totaled SEK -13.8 (-21.6) -68.2) million.million. · Earnings per share, basic and diluted, · Earnings per share, basic wereand diluted, were SEK -0.30 (-0.44).SEK -0.09 (-0.14). · Cash flow from operating activities for · Cash flow from operating the period totaled SEK -40.3 (-65.4)

Enzymatica’s Board of Directors decides on a new rights issue of SEK 27.4 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors of Enzymatica AB (publ) (“Enzymatica” or the “Company”) has decided to carry out a rights issue amounting to SEK 27.4 million, with preferential rights for existing shareholders, by exercising the

Interim report Q3/2023: Research results that reshape the competitive landscape

Third quarter January-September · Net sales reached SEK · Net sales reached SEK13.3 (18.5) million. 35.1 (32.3) million. · The operating result · The operating resulttotaled SEK -8.7 (-12.6) totaled SEK -34.3 (-46.6)million. million. · Earnings per share, basic · Earnings per share, basicand diluted, were SEK -0.06 and diluted, were SEK -0.22(-0.08). (-0.31). · Cash flow from operating · Cash flow from operatingactivities totaled SEK -16.0 activities totaled SEK -

Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat

The first results from an ongoing independent clinical study at the University of Kent, UK, show that ColdZyme® significantly reduces the viral load of rhinovirus, the predominant cause of the common cold. Additionally, participants who used ColdZyme experienced significantly less severe sore throat symptoms than those who used placebo. The researchers are assessing the efficacy of ColdZyme mouth spray on upper respiratory tract infection (URTI) parameters, including viral load, in a randomized, double-blind, and placebo-controlled trial, under free-living conditions in endurance

New study: ColdZyme breaks viral infection cycle – significantly reducing influenza viral load

ColdZyme® reduces viral load by more than 99 percent when applied onto human cells that have been infected with influenza A (H3N2), compared to infected cells that were treated with salt solution. According to researchers at the Medical University of Innsbruck, ColdZyme breaks the infection cycle, limiting the spread of viruses to more cells. The researchers believe that ColdZyme would have the same effect on other respiratory viruses. ColdZyme mouth spray is sold in more than 30 markets on four continents, also under brand names such as ViruProtect®, Bisolviral® and ADerogyl®. Previous

Interim report Q2/2023: An exciting and important time ahead

Q2 H1 · Net sales reached SEK 8.8 (9.6) · Net sales reached SEK 21.8 (13.8)million. million. · The operating result totaled SEK · The operating result totaled SEK-11.2 (-15.9) million. -25.5 (-34.0) million. · Earnings per share, basic and · Earnings per share, basic anddiluted, were SEK -0.07 (-0.10). diluted, were SEK -0.16 (-0.22). · Cash flow from operating · Cash flow from operatingactivities totaled SEK -9.5 (-21.5) activities totaled SEK -21.7 (-31.7)

Bulletin from Annual General Meeting of Enzymatica AB (publ)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.Enzymatica AB (publ) held its annual general meeting on 4 May 2023. At the annual general meeting, the following resolutions were made. Income statements and balance sheetsThe general meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet for the fiscal year of 2022. Disposition of the company’s profit or loss The general

Interim report Q1/2023: Strong start to the year – Enzymatica’s growth journey continues according to plan

First quarter · Net sales reached SEK 13.0 (4.2) million. · The operating result totaled SEK -14.4 (-18.1) million. · Earnings per share, basic and diluted, were SEK -0.09 (-0.12). · Cash flow from operating activities totaled SEK -12.2 (-10.2) million.Cash flow was impacted by payment of one-off compensation to partners totalingSEK 5.6 million.   Significant events during the quarter Significant events after the quarter    · No significant events were reported · No significant events were reportedduring the

Enzymatica publishes annual report for 2022

The annual report for Enzymatica 2022 was published today (in Swedish) on the company’s website: https://www.enzymatica.com/sv/investerare/finansiella-rapporter/. The annual report is only available in digital format. An English short version of the annual report is available on: https://www.enzymatica.com/investors/financial-reports/.  FOR MORE INFORMATION, PLEASE CONTACT:  Claus Egstrand, CEO, Enzymatica ABPhone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com Stefan Olsson, Communication Manager, Enzymatica ABPhone: +46 (0) 708 55 11 85 | Email: stefan.olsson@

Notice of Annual General Meeting 2023 in Enzymatica AB (publ)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The annual general meeting of Enzymatica AB (publ), reg. no. 556719-9244 (the “Company”), will be held on 4 May 2023 at 14:30, Elite Hotel Ideon, Scheelevägen 27 in Lund. Notification etc. Those who wish to participate in the annual general meeting must: (i)      be listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances as per the record date of 25

Interim report Q4/2022: A year that laid the foundation for growth

Significant events during the quarter Significant events after the quarter · On October 31, the journal · No significant events were reportedRespiratory Research published an in after the end of the quarter.-vitro study from the MedicalUniversity of Innsbruck which showsthat ColdZyme blocks the widespreadand highly transmissible omicronvariants BA.4 and BA.5 from adheringto and infecting human cells.According to the researchers whoconducted the study, this findingmeans the possibility that ColdZymecan be applied to prevent the spreadof SARS-CoV-2.

Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes

The University of Kent (UK) is working with Enzymatica on a new double-blind, placebo-controlled study to explore the preventative effects of ColdZyme on upper respiratory infections in elite athletes. A previous study showed treatment with ColdZyme can reduce the number of lost training days. Enzymatica has initiated a new study into the effect of ColdZyme on the upper respiratory resilience of competitive endurance athletes – a group to which viral protection is a key priority. The study is being undertaken by the University of Kent, UK, and builds on a previous 2020 study by the same

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe